证券代码：002424 证券简称：ST 百灵 公告编号：2024-058 贵州百灵企业集团制药股份有限公司 关于控股股东部分股份办理质押延期购回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 3、最近一年又一期控股股东姜伟先生不存在非经营性资金占用、 违规担保等侵害上市公司利益的情形。 公司控股股东姜伟先生质押股份数量为 245,346,161 股，累计占 其所持公司股份数量比例 100%，请投资者注意相关风险。 近日，贵州百灵企业集团制药股份有限公司（以下简称"本公 司"） 接到控股股东姜伟先生函告，获悉姜伟先生近日将已质押给海 通证券股份有限公司的部分股票办理股票质押式回购交易延期购回， 具体事项如下： 股东 名称 是否为 控股股 东或第 一大股 东及其 一致行 动人 本次质押数 量（股） 占其所 持股份 比例 占公司 总股本 比例 是否 为限 售股 是否 为补 充质 押 质押起始 日 质押到期 日 延期购 回后到 期日 质权 人 质押用 途 姜伟 是 12,875,998 5.25% 0.92% 否 否 2017 年 8 月 22 日 ...

| 表 | | --- | | 债 | | 负 | | 产 | | 奖 | | 井 | | 4 I | | 编制单位:贵州百灵企业集团制药股份有限公司 | | | | | | | 会合01表 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 单位:人民币元 | | | | | 上年年末数 | 负债和所有者权益 (或股东权益) | 注释 름 | 期末数 | 上年年末数 | | 流动资产: | | | | | | | | | 货币资金 | | | 417, 938, 537. 62 | 流动负债: | | | | | 结算备付金 | | | | 短期借款 | 23 | 1, 460, 265, 191. 73 | 1, 436, 017, 612. 52 | | | | | | 向中央银行借款 | | | | | 拆出资金 | | | | 拆入资金 | | | | | 父易性金融资 | | | | 父易性金融负债 | | | | | 衍生金融资产 | | | | 衍生金融负债 | | | | | 应收票据 | 2 | 13, 3 ...

Financial Performance - Guizhou Bailing reported no cash dividends or stock bonuses for the 2024 fiscal year[1]. - The company's operating revenue for the first half of 2024 was CNY 2,142,835,969.60, representing a 12.81% increase compared to CNY 1,899,531,458.36 in the same period last year[11]. - Net profit attributable to shareholders decreased by 27.32% to CNY 87,461,409.09 from CNY 120,338,248.40 year-on-year[11]. - The net profit from non-recurring gains and losses dropped by 72.28% to CNY 32,563,183.46 compared to CNY 117,463,745.33 in the previous year[11]. - The net cash flow from operating activities was negative at CNY -30,370,447.37, a decline of 125.02% from CNY 121,367,095.84 in the same period last year[11]. - The total assets at the end of the reporting period were CNY 7,487,694,865.06, an increase of 1.89% from CNY 7,349,081,335.53 at the end of the previous year[11]. - The weighted average return on equity decreased to 2.50% from 3.01% year-on-year[11]. - The company reported a basic and diluted earnings per share of CNY 0.06, down 33.33% from CNY 0.09 in the previous year[11]. - The company received government subsidies amounting to CNY 34,161,420.51 during the reporting period[13]. - The company’s net profit for the first half of 2024 was CNY 162,316,204.81, compared to CNY 140,662,883.66 in the first half of 2023, indicating a growth of 15.4%[111]. Business Strategy and Development - The report emphasizes the importance of risk awareness for investors regarding future plans and strategies[1]. - The management discussion section highlights the company's strategies for addressing risks and challenges[1]. - The company continues to focus on the development of new products and technologies[1]. - The company is focusing on the development of new extraction technologies and quality control methods to enhance the efficacy and safety of traditional Chinese medicine[16]. - The company aims to strengthen its leading position in the苗药 field and become a core competitive enterprise in the中成药 sector[22]. - The company is actively expanding its market presence and enhancing its production capabilities through the establishment of a large-scale manufacturing platform and a comprehensive marketing platform[22]. - The company is focusing on technological innovation and increasing investment in R&D to enhance its product offerings and market competitiveness[22]. - The company is committed to addressing the growing healthcare needs driven by an aging population and increasing health awareness among consumers[18]. - The company is enhancing its compliance with regulatory requirements, which is expected to support its sustainable development[17]. Research and Development - The company submitted 25 new Chinese medicine drug applications by June 2024, with a year-on-year increase of 150% in submissions[16]. - The company has established various R&D platforms, including a national-level joint engineering research center and a postdoctoral research station, to enhance its core competitiveness in drug development[30]. - The company has a total of 85 valid patents, including 54 domestic invention patents, 14 design patents, and 17 utility model patents[29]. - The company's R&D investment decreased by 46.31% to CNY 26,197,053.74 from CNY 48,795,249.56 in the previous year, influenced by the varying stages of R&D projects[34]. - The company is focusing on improving research and development management to address risks associated with drug development cycles and uncertainties[55]. Market and Sales - The company has a diverse product portfolio, including key products such as银丹心脑通软胶囊, 咳速停糖浆, and 小儿柴桂退热颗粒, which hold significant market shares in their respective categories[19][20]. - The revenue from traditional Chinese medicine products amounted to CNY 2,020,485,196.9, accounting for 94.29% of total revenue, with a year-on-year growth of 16.61%[37]. - The commercial segment saw a significant revenue increase of 46.10%, with a gross profit margin of 59.98%, reflecting a 6.55% improvement in cost management[36]. - The company has established a marketing network covering over 32 provinces, cities, and autonomous regions, with more than 600,000 terminal customers and over 100,000 signed VIP customers[33]. - The company has expanded its marketing efforts to include grassroots medical institutions, successfully developing over 100,000 such institutions[33]. Financial Management and Compliance - The financial report is guaranteed to be true, accurate, and complete by the company's management[1]. - The company plans to enhance its financial management and internal control systems to ensure compliance and effective decision-making[25]. - The company is committed to improving compliance with securities laws and regulations following a warning from the regulatory authority[76]. - The company’s board and management are taking measures to enhance internal controls and prevent operational risks[73]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months[132]. Environmental and Social Responsibility - The company has established a dedicated environmental protection department to oversee compliance with environmental regulations and standards[62]. - The company has implemented a comprehensive environmental management system and emergency response plans for environmental incidents[62]. - The company has achieved a daily wastewater treatment capacity of 5,000 tons with the completion of the second phase of its wastewater treatment and reuse project, which is set to be operational soon[68]. - The company actively participates in social welfare activities, supporting local education, culture, and health initiatives, and has built traditional Chinese medicine planting bases in impoverished areas[68]. - The company has received national-level honors such as "Green Factory" and "Water-saving Enterprise," reflecting its commitment to environmental protection and sustainable practices[67]. Shareholder and Corporate Governance - The company held two temporary shareholder meetings and one annual shareholder meeting in 2024, with investor participation rates of 0.49%, 0.58%, and 1.36% respectively[58][59]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[59]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[100]. - The company completed a share buyback of 20,491,812 shares, accounting for 1.47% of the total share capital, with a total transaction amount of RMB 119,587,599.20[95]. - The largest shareholder, Jiang Wei, holds 17.39% of the shares, totaling 245,346,284 shares, with 61,336,571 shares pledged[97]. Regulatory and Legal Matters - The company failed to disclose performance forecasts within the required timeframe after the end of the 2023 fiscal year, violating regulations[76]. - The company has not engaged in any significant related party transactions during the reporting period[77]. - There were no major litigation or arbitration matters during the reporting period[75]. - The company has not experienced any bankruptcy reorganization matters during the reporting period[74]. - The company has not provided any non-operating fund occupation by controlling shareholders or related parties during the reporting period[70]. Accounting and Financial Reporting - The financial statements have been approved by the board of directors on August 27, 2024, reflecting the company's financial status and operating results[130]. - The company adheres to the accounting standards for enterprises, ensuring the financial statements are true and complete[134]. - The company has implemented new accounting policies effective January 1, 2024, including the classification of current and non-current liabilities, with no impact on financial statements[198]. - The company recognizes revenue when the customer obtains control of the goods or services, typically at the point of delivery, and is measured based on the transaction price allocated to each performance obligation[188]. - The company assesses the carrying value of expected liabilities and adjusts them based on the best estimate of the required expenditures[187].

单位：万元 | | 贵州百灵企业集团生物科 | 子公司 | 其他应收款 | 1,489.09 | 13.19 | 103.20 | 1,399.08 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 技肥业有限公司 | | | | | | | | | | 贵州百灵企业集团纯净水 | 子公司 | 其他应收款 | 69.20 | 4.38 | | 73.58 | 非经营性往来 | | | 有限公司 | | | | | | | | | | 百灵大健康产业发展（南 | 子公司 | 其他应收款 | 613.10 | | | 613.10 | 非经营性往来 | | | 京）有限公司 | | | | | | | | | | 云南红灵生物科技有限公 | 子公司 | 其他应收款 | 4,637.55 | 1,087.50 | 215.95 | 5,509.10 | 非经营性往来 | | | 司 | | | | | | | | | | 贵州百灵中医糖尿病医院 | 子公司 | 其他应收款 | 10,956.46 | 94.03 | 94.0 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2024-054 贵州百灵企业集团制药股份有限公司 关于第六届董事会第十一次会议决议的公告 经现场及通讯投票表决，会议审议通过了以下议案： 议案一、审议通过《2024年半年度报告及摘要》。 关于《2024年半年度报告》及《2024年半年度报告摘要》详见公 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 一、会议召开情况 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）第 六届董事会第十一次会议由公司董事长姜伟先生召集，会议通知于 2024 年 8 月 16 日以专人送达、电子邮件、电话等通讯方式发出。 2、本次董事会于 2024 年 8 月 27 日上午 10:00 在公司三楼会议 室以现场结合通讯方式召开。 3、本次董事会应参会表决董事共 9 人，实际参会表决的董事 9 人。其中独立董事胡坚、晏国菀、杨明、张洪武以通讯方式进行表决。 4、本次董事会由董事长姜伟先生主持，公司监事和高级管理人 员列席了本次董事会。 5、本次董事会的召集、召开符合《公司法》、《公司章程》、《董事 会议事规则》及相关 ...

证券代码：002424 证券简称：ST百灵 公告编号：2024-055 贵州百灵企业集团制药股份有限公司 关于第六届监事会第七次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 一、监事会召开情况 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）第 六届监事会第七次会议由公司监事会主席周春刚先生召集，会议通知 于2024年8月16日以专人送达、电子邮件、电话等通讯方式发出。 2、本次监事会于 2024 年 8 月 27 日下午 2:00 在公司三楼会议室 以现场表决方式召开。 3、本次监事会应到监事5人，实到5人。 三、备查文件 1、经与会监事签字并加盖监事会印章的监事会决议； 4、本次监事会由监事会主席周春刚先生主持，公司高级管理人 员列席了本次会议。 5、本次监事会的召集、召开符合《公司法》、《公司章程》、 《监事会议事规则》及相关法规的规定，会议召开合法有效。 二、监事会会议审议情况 本次会议经过充分讨论，会议审议通过了以下议案： 议案一、审议通过《2024年半年度报告及摘要》。 经审核，监事会认为：董事会编制和审核《2024年半 ...

深圳证券交易所文件 深证上〔2024〕670 号 司）及相关当事人存在以下违规行为： 2024 年 4 月 30 日，公司披露的《2023 年年度报告》显示， 公司 2023 年度归属于上市公司股东的净利润为-4.15 亿元，较 2022 年度由盈转亏。公司未在规定期限内披露 2023 年度业绩预 告。 关于对贵州百灵企业集团制药股份有限公司 及相关当事人给予公开谴责处分的决定 当事人： 贵州百灵企业集团制药股份有限公司,住所：贵州省安顺市 经济技术开发区西航路 212 号； 姜伟，贵州百灵企业集团制药股份有限公司董事长； 牛民，贵州百灵企业集团制药股份有限公司总经理兼董事会 秘书； 李红星，贵州百灵企业集团制药股份有限公司财务负责人。 经查明，贵州百灵企业集团制药股份有限公司（以下简称公 — 1 — 公司的上述行为违反了本所《股票上市规则（2023 年 8 月修 订）》第 1.4 条、第 2.1.1 条第一款、第 5.1.1 条第一款第一项 的规定。 公司董事长姜伟、总经理兼董事会秘书牛民、财务负责人李 红星未能恪尽职守、履行勤勉尽责义务，违反了本所《股票上市 规则（2023 年 8 月修订）》第 1.4 ...

证券代码：002424 证券简称：ST 百灵 贵州百灵企业集团制药股份有限公司投资者关系活动记录表 编号：2024-004 投资者关系活动 ☑特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 银华基金 吴颖 人员姓名 中邮证券 蔡明子 时间 2024 年 8 月 7 日 地点 公司会议室 上市公司接待人 总经理兼董事会秘书：牛民 员姓名 证券事务代表：陈智 1、公司营销改革情况？ 答：公司 21 年 11 月开始进行营销改革以来，持续推进销 售业务工作全面升级，销售部改为营销中心，新设市场监管部， 将云南、四川、贵州、河南、广东、江苏、山东、湖北、湖南 九个省区销售模式调整为直营制，改变以往单纯考核增长率的 方式，引入人均效能、店均效能等考核项，合理制定考核指标， 投资者关系活动 充分调动各级销售人员积极性，通过适时推进股权激励计划等 主要内容介绍 方式，使广大员工获益与公司发展相契合，使得个人的收入从 原本的财产性收入转变为依托于上市公司平台而衍生出的资 产性收入。同时坚持以利润为首要导向，优化品种结构和价格 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2024-052 贵州百灵企业集团制药股份有限公司 回购股份实施结果暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）于 2024 年 2 月 2 日召开第六届董事会第六次会议，审议通过了《关于回购公 司股份方案的议案》，同意公司使用自有资金以集中竞价的方式回购 公司部分股份，用于后期实施股权激励或员工持股计划。回购的资金 总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含）， 回购价格不超过人民币 11.85 元/股（含），回购股份的实施期限为自 董事会审议通过回购股份方案之日起不超过 6 个月。具体内容详见公 司 2024 年 2 月 3 日在《证券时报》《证券日报》《中国证券报》和 巨潮资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案的 公告暨回购报告书》（公告编号：2024-002）。 截至 2024 年 8 月 2 日，公司本次回购股份实施期限已届满，本 次股份回购计划已实施完 ...

证券代码：002424 证券简称：ST 百灵 公告编号：2024-053 贵州百灵企业集团制药股份有限公司（以下简称"公司"）及相 关责任人于近日分别收到中国证券监督管理委员会贵州监管局（以下 简称"贵州证监局"）出具的行政监管措施决定书：《关于对贵州百灵 企业集团制药股份有限公司采取责令改正措施的决定》（〔2024〕24 号） （以下简称"《决定书 1》"）、《关于对姜伟、牛民、李红星、郑荣采取 监管谈话措施的决定》（〔2024〕25 号）（以下简称"《决定书 2》"）， 《决定书 1》《决定书 2》统称《决定书》，现将有关情况公告如下： 一、《决定书》主要内容 （一）《决定书 1》 "贵州百灵企业集团制药股份有限公司： 经查，你公司存在以下问题： 贵州百灵企业集团制药股份有限公司 关于公司及相关责任人收到行政监管措施决定书的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上述行为违反了《上市公司信息披露管理办法》(证监会令第 40 号)第二条第一款、《上市公司信息披露管理办法》(证监会令第 182 号)第三条第一款的规定。 根据《上市公司信息披露管 ...